From monitoring to vigilance about patient adherence to new oral anticoagulants
Authors:
Open Access
- 26 September 2013
- journal article
- research article
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 16 (1) , 149
Abstract
Ambivalence envelops the European Heart Rhythm Association Practical Guide1 on the use of new oral anticoagulants (NOACs). The Guide recites the NOACs' marketing claim of ‘predictable effect without need for monitoring’, but proclaims that ‘therapy prescription with the new class of drugs requires vigilance’. ‘Monitoring’, thus renamed ‘vigilance’, draws prescribers into an array of partial measures of NOAC actions of limited value, e.g. interpretations where, to be viable, knowledge of the time since the last-taken dose is required but where approximately one-third of patient-reported data on dose-timing are substantially erroneous, even in controlled clinical trials settings.Keywords
This publication has 5 references indexed in Scilit:
- European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillationEP Europace, 2013
- Identification and Assessment of Adherence-Enhancing Interventions in Studies Assessing Medication Adherence Through Electronically Compiled Drug Dosing Histories: A Systematic Literature Review and Meta-AnalysisDrugs, 2013
- Adherence to Medications: Insights Arising from Studies on the Unreliable Link Between Prescribed and Actual Drug Dosing HistoriesAnnual Review of Pharmacology and Toxicology, 2012
- Estimation of the comparative therapeutic superiority of QD and BID dosing regimens, based on integrated analysis of dosing history data and pharmacokineticsJournal of Pharmacokinetics and Pharmacodynamics, 2007
- Time to stop counting the tablets?Clinical Pharmacology & Therapeutics, 1989